Hengyuan Li

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Dna Methylation

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Youyou Shao, Jingying Zhang, Zhi Feng, Wei Wu, Xiaotian Zhao, Minyi Zhu, Yao Xiao, Jiaohui Pang, Junfei Zhu, Hao Qu, Minchi Yuan, Guojie Xia, Meng Liu, Hengyuan Li
Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study. Cancer science 115 (8) (2024)
Youyou Shao, Jingying Zhang, Zhi Feng, Wei Wu, Xiaotian Zhao, Minyi Zhu, Yao Xiao, Jiaohui Pang, Junfei Zhu, Hao Qu, Minchi Yuan, Guojie Xia, Meng Liu, Hengyuan Li
Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study. Cancer science (2024)
Youyou Shao, Jingying Zhang, Zhi Feng, Wei Wu, Xiaotian Zhao, Minyi Zhu, Yao Xiao, Jiaohui Pang, Junfei Zhu, Hao Qu, Minchi Yuan, Guojie Xia, Meng Liu, Hengyuan Li
Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study. Cancer science 115 (8) (2024)
Youyou Shao, Jingying Zhang, Zhi Feng, Wei Wu, Xiaotian Zhao, Minyi Zhu, Yao Xiao, Jiaohui Pang, Junfei Zhu, Hao Qu, Minchi Yuan, Guojie Xia, Meng Liu, Hengyuan Li
Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study. Cancer science 115 (8) (2024)